You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾美疫苗(06660.HK):mRNA帶狀皰疹疫苗免疫指標顯著高於國際市售重組亞單位疫苗產品已在美國申報臨牀
格隆匯 02-23 19:10

格隆匯2月23日丨艾美疫苗(06660.HK)公告,集團按照既定公司戰略積極推進疫苗產品管線的開發,利用mRNA技術平臺優勢,通過持續的技術創新,快速推進mRNA疫苗系列產品的研發,mRNA帶狀皰疹疫苗已於近日向美國食品和藥品監督管理局(FDA)申報臨牀,標誌着集團全球化戰略取得了新的進展。

臨牀前動物試驗中,第三方檢測單位的檢測結果顯示:集團mRNA帶狀皰疹疫苗特異性T細胞免疫、特異性IgG抗體滴度、膜抗原熒光抗體(FAMA)滴度,均顯著高於國際市售重組亞單位對照疫苗。

目前國際上尚無mRNA帶狀皰疹疫苗獲批上市,帶狀皰疹疫苗在目標人羣中接種率僅爲0.1%左右,存在巨大提升空間。2024年度GSK的帶狀皰疹疫苗全球銷售額約43.10億美元。根據行業顧問灼識諮詢預測,預計到2030年,帶狀皰疹疫苗在中國的市場規模將達到約人民幣200億元,全球的市場規模將達到約239億美元。該產品獲批上市後,將給本集團帶來可觀的業績增長,mRNA帶狀皰疹疫苗在安全性和免疫原性上的優勢,有望重塑市場格局。

集團是中國最早開發mRNA疫苗產品的企業之一,也是國內第一批取得mRNA技術自主專利的疫苗企業,具有成熟的mRNA疫苗研發體系。集團現已打通mRNA疫苗研發、生產等全生命週期的流程,在完成臨牀後可迅速實現mRNA疫苗產品的產業化,加快疫苗產品的商業化進程。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account